Gilead Oncology Trodelvy Dosing and Administration | GileadPro

This website is developed and funded by Gilead Sciences Ltd and intended for healthcare professionals in the United Kingdom. Adverse Event Reporting

Oncology Prescribing Information

The recommended dose of Trodelvy® is 10 mg/kg administered as an intravenous infusion once weekly on Days 1 and 8 of 21-day treatment cycles1


Watch this short video to learn more about how to appropriately dose and administer Trodelvy®.

References
  1. Trodelvy® UK Summary of Product Characteristics. Gilead Sciences Ltd. Available at: https://www.medicines.org.uk/emc/product/12880. Accessed May 2025.
Stay up to date

Receive email updates from Gilead, including promotional communications.

Register

May 2025 UKI-TRO-0275

Adverse events should be reported.

For the UK, reporting forms and information can be found at www.mhra.gov.uk/yellowcard or via the Yellow Card app (download from the Apple App Store or Google Play Store). For IE, reporting forms and information can be found at www.hpra.ie and can be reported to HPRA on +353 1 6764971. Adverse events should also be reported to Gilead to [email protected] or +44(0) 1223 897500 or +353(0) 21 482 5999.